Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

A 21-year-old man shared his 2.5-year experience with hair loss treatments, including 1mg Propecia (finasteride) nightly, 12.5% Minoxidil once daily, 2% Nizoral shampoo 2-4 times a week, and later 5% Minoxidil once daily. He experienced minor side effects like watery semen and itchy scalp, and while he's seen fluctuations in hair growth, he's generally happy with the results and is considering experimental treatments like CB-03-01 and RU58841.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.

A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

Clascoterone is seen as a promising topical treatment for hair loss, similar to finasteride but without side effects, though concerns exist about its long-term effectiveness. Other treatments discussed include topical minoxidil, ketoconazole, microneedling, and oral options like dutasteride and minoxidil.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

Fin and minoxidil, in combination with dermarolling, as an effective path for hair growth. The post also provides advice about needle depth and frequency, as well as other treatments (foam and oral) which may be beneficial.

People are discussing where to buy Alfatradiol in Canada, avoiding eBay due to past issues. They share experiences and links to potential sellers, with some users noting the lower potency of available Alfatradiol products.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation humorously discusses hair loss and potential treatments like finasteride and minoxidil. It includes playful banter and jokes about appearance and identity.

A 20-year-old male experienced mental fog after resuming topical minoxidil for hair loss, questioning if it's due to interactions with antidepressants. Suggestions included trying a lower concentration of minoxidil or alternatives like copper peptides.

The user started using topical minoxidil 5% and ketoconazole shampoo for hair loss, noticing minimal progress after three months, with fine hairs appearing. They experienced a setback when reducing the application to once a day but resumed twice daily applications.

A user started using oral minoxidil (2.5 mg) and dutasteride (1 mg) for hair loss three months ago and noticed no side effects, possibly due to regular exercise. They speculate a possible link between COVID-19 and accelerated hair loss.

A user is excited to start using Pyriltamide for hair loss after experiencing side effects from topical finasteride. Other users discuss the potential and skepticism of Pyriltamide compared to older treatments like finasteride and RU58841.

A 19-year-old shares his hair loss experience and treatment routine, which includes 1mg finasteride daily, 2mg oral minoxidil daily, ketoconazole shampoo every 2 days, and a healthy lifestyle. He notes that oral minoxidil is showing better results than topical minoxidil.